Impact Of Treatment Modality On Survival Of Figo Stage Iib Cervical Cancer: A Propensity-Score Matching Analysis Based On Impact Of Treatment Modality On Survival Of Figo Stage Iib Cervical Cancer: A Propensity-Score Matching Analysis Based On Surveillance, Epidemiology, And End Results Database

Introduction/Background Concurrent chemoradiotherapy is the standard of care for FIGO stage IIB cervical cancer. However, there remains a role of surgical treatment in these patients. The aim of this study was to investigate the impact of treatment modality on survival of patients with stage IIB cervical cancer. Methodology Patients with stage IIB cervical cancer registered in the Surveillance, Epidemiology, and End Results database between 1988 and 2015 were identified and grouped according to their treatment modalities. For patients identified as surgical group, only those receiving both hysterectomy and chemotherapy were included. For patients identified as non-surgical group, only those receiving both beam radiation and chemotherapy were included. A 1:1 propensity score matching (PSM) were performed to adjust the baseline characteristics. Results A total of 4718 eligible patients were identified, of whom 902 were in the surgical and 3816 in the non-surgical group. Patients undergoing surgery were younger and were more likely to be married, non-Black race, non-squamous cell carcinoma, N1 stage, and have medical insurance, small tumor compared to those receiving non-surgical treatment (P=0.037 for insurance; P Conclusion The treatment modality has significant impact on survival of patients with stage IIB cervical cancer. Surgical treatment should be preferentially considered in patients with non-squamous-cell histology. Chemoradiotherapy with completion surgery may be the most effective treatment. However, when non-surgical treatment was selected, the omission of brachytherapy should be avoided. Disclosures The authors declare that they have no competing interests.